- Home
- ALXO vs PLX Comparison
ALXO vs PLX Comparison
Compare ALXO & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | PLX |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.8M | 207.1M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ALXO | PLX |
|---|---|---|
| Price | $1.18 | $2.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $4.60 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 836.2K |
| Earning Date | 11-06-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $1.65 |
| 52 Week High | $2.66 | $3.19 |
Technical Indicators
Market Signals| Indicator | ALXO | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 42.44 |
| Support Level | $0.86 | $2.21 |
| Resistance Level | $1.29 | $2.75 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 69.20 | 19.67 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.